These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31506870)

  • 1. Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy.
    Gendre T; Planté-Bordeneuve V
    Clin Auton Res; 2019 Sep; 29(Suppl 1):25-31. PubMed ID: 31506870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis).
    Gonzalez-Duarte A
    Clin Auton Res; 2019 Apr; 29(2):245-251. PubMed ID: 29511897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    González-Duarte A; Berk JL; Quan D; Mauermann ML; Schmidt HH; Polydefkis M; Waddington-Cruz M; Ueda M; Conceição IM; Kristen AV; Coelho T; Cauquil CA; Tard C; Merkel M; Aldinc E; Chen J; Sweetser MT; Wang JJ; Adams D
    J Neurol; 2020 Mar; 267(3):703-712. PubMed ID: 31728713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
    Conceição I
    Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review.
    Cruz MW
    Clin Auton Res; 2019 Sep; 29(Suppl 1):19-24. PubMed ID: 31407119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management.
    Palma JA; Gonzalez-Duarte A; Kaufmann H
    Clin Auton Res; 2019 Sep; 29(Suppl 1):33-44. PubMed ID: 31452021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management.
    Alcantara M; Mezei MM; Baker SK; Breiner A; Dhawan P; Fiander A; Fine NM; Hahn C; Katzberg HD; Khayambashi S; Massie R; Matte G; Putko B; Siddiqi Z; Delgado D; Bril V
    Can J Neurol Sci; 2022 Jan; 49(1):7-18. PubMed ID: 33631091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR).
    Vita GL; Stancanelli C; Gentile L; Barcellona C; Russo M; Di Bella G; Vita G; Mazzeo A
    Neuromuscul Disord; 2019 Mar; 29(3):213-220. PubMed ID: 30718023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review.
    Gonzalez-Duarte A; Valdés-Ferrer SI; Cantú-Brito C
    Clin Auton Res; 2019 Sep; 29(Suppl 1):1-9. PubMed ID: 31473866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial Oculo-Leptomeningeal Transthyretin Amyloidosis Caused by Leu55Arg Mutation.
    Kleefeld F; Knebel F; Eurich D; Schatka I; Blüthner E; Schönfeld S; Amthauer H; Hahn K
    J Neuromuscul Dis; 2020; 7(4):515-519. PubMed ID: 32741838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7.
    Dyck PJB; González-Duarte A; Obici L; Polydefkis M; Wiesman JF; Antonino I; Litchy WJ; Dyck PJ
    J Neurol Sci; 2019 Oct; 405():116424. PubMed ID: 31445300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure and orthostatic hypotension as measures of autonomic dysfunction in patients from the transthyretin amyloidosis outcomes survey (THAOS).
    González-Duarte A; Barroso F; Mundayat R; Shapiro B
    Auton Neurosci; 2019 Dec; 222():102590. PubMed ID: 31726319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.
    De Bleecker JL; Claeys KG; Delstanche S; Van Parys V; Baets J; Tilleux S; Remiche G
    Acta Neurol Belg; 2023 Jun; 123(3):1029-1037. PubMed ID: 36829087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Red flags in patients with hereditary transthyretin amyloidosis at diagnosis in a non-endemic area of Spain.
    Silva-Hernández L; Horga Hernández A; Valls Carbó A; Guerrero Sola A; Montalvo-Moraleda MT; Galán Dávila L
    Neurologia (Engl Ed); 2023 Mar; 38(2):87-92. PubMed ID: 36396096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    Obici L; Berk JL; González-Duarte A; Coelho T; Gillmore J; Schmidt HH; Schilling M; Yamashita T; Labeyrie C; Brannagan TH; Ajroud-Driss S; Gorevic P; Kristen AV; Franklin J; Chen J; Sweetser MT; Wang JJ; Adams D
    Amyloid; 2020 Sep; 27(3):153-162. PubMed ID: 32131641
    [No Abstract]   [Full Text] [Related]  

  • 16. Widespread Cardiac and Vasomotor Autonomic Dysfunction in Non-Val30Met Hereditary Transthyretin Amyloidosis.
    Koike H; Nakamura T; Nishi R; Ikeda S; Kawagashira Y; Iijima M; Katsuno M; Sobue G
    Intern Med; 2018 Dec; 57(23):3365-3370. PubMed ID: 29984770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burden of hereditary transthyretin amyloidosis on quality of life.
    Yarlas A; Gertz MA; Dasgupta NR; Obici L; Pollock M; Ackermann EJ; Lovley A; Kessler AS; Patel PA; White MK; Guthrie SD
    Muscle Nerve; 2019 Aug; 60(2):169-175. PubMed ID: 31093980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric emptying in hereditary transthyretin amyloidosis: the impact of autonomic neuropathy.
    Wixner J; Karling P; Rydh A; Hörnsten R; Wiklund U; Anan I; Suhr OB
    Neurogastroenterol Motil; 2012 Dec; 24(12):1111-e568. PubMed ID: 22897426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis.
    Dyck PJB; Coelho T; Waddington Cruz M; Brannagan TH; Khella S; Karam C; Berk JL; Polydefkis MJ; Kincaid JC; Wiesman JF; Litchy WJ; Mauermann ML; Ackermann EJ; Baker BF; Jung SW; Guthrie S; Pollock M; Dyck PJ
    Muscle Nerve; 2020 Oct; 62(4):509-515. PubMed ID: 32654156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis.
    Obici L; Suhr OB
    Clin Auton Res; 2019 Sep; 29(Suppl 1):55-63. PubMed ID: 31452022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.